
Precision Biosciences (DTIL) Stock Forecast & Price Target
Precision Biosciences (DTIL) Analyst Ratings
Bulls say
Precision BioSciences Inc. exhibits a promising outlook driven by the encouraging initial data from its PBGENE-HBV program and the positive implications for its ARCUS platform, suggesting a de-risking of its in vivo gene editing pipeline. The company's collaboration with iECURE, which recently reported favorable first-in-infant data for the ECUR-506 program, enhances the validation of the ARCUS technology and underscores its potential in treating genetic disorders. With the anticipated advancements and robust preclinical data indicating a favorable safety profile, Precision's strategic position in genome editing may attract significant investor interest and support future growth.
Bears say
Precision BioSciences faces significant financial challenges stemming from the inherent risks associated with its novel gene editing platform, ARCUS, which may lead to long-term regulatory delays and safety concerns that can adversely affect clinical development timelines. The company is heavily reliant on its intellectual property for revenue generation, and any potential legal disputes or claims could further compromise its market position and profitability. Additionally, a negative scenario predicts that all of its pipeline programs could fail in clinical studies, severely impacting its future revenue prospects and overall market valuation.
This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Precision Biosciences (DTIL) Analyst Forecast & Price Prediction
Start investing in Precision Biosciences (DTIL)
Order type
Buy in
Order amount
Est. shares
0 shares